title: Atrial fibrillation after esophageal cancer surgery: an analysis of 207 consecutive patients.
abstract: OBJECTIVE
  The aim of this study was to identify perioperative risk factors that are associated with postoperative atrial fibrillation (AF) and the outcomes of different pharmacological interventions in esophageal cancer patients who underwent transthoracic esophagectomy.
  
  
  METHODS
  This study included 207 patients who underwent a transthoracic esophagectomy for esophageal cancer resection by a single surgeon from January 1, 2004, through December 31, 2010.
  
  
  RESULTS
  Postoperative AF occurred in 19 patients (9.2 %), all of whom received antiarrhythmic drug therapy at the early stage. Antiarrhythmic treatment was effective in 12 cases (63.2 %). In this study, landiolol hydrochloride, an ultrashort-acting β1-selective β-blocker, was the first-line therapy for postoperative AF. A multivariate logistic regression analysis showed that postoperative AF was significantly associated with the use of an ileo-colon for reconstruction after esophagectomy (P = 0.0023, odds ratios [OR] = 13.6) and with the presence of tachycardia with a heart rate of >100 bpm on postoperative day (POD) 1 (P = 0.0004, OR = 18.4).
  
  
  CONCLUSIONS
  Postoperative AF is associated with the use of a colon conduit for reconstruction after esophagectomy and with tachycardia with a heart rate >100 bpm on POD 1. Identifying patients at high risk for postoperative AF will allow for more direct application of pharmacological methods of prophylaxis.
authors.affiliation: Second Department of Surgery, Wakayama Medical University, Wakayama, Japan.
authors.forename: Toshiyasu
authors.initials: T
authors.lastname: Ojima
authors.forename: Makoto
authors.initials: M
authors.lastname: Iwahashi
authors.forename: Mikihito
authors.initials: M
authors.lastname: Nakamori
authors.forename: Masaki
authors.initials: M
authors.lastname: Nakamura
authors.forename: Masahiro
authors.initials: M
authors.lastname: Katsuda
authors.forename: Takeshi
authors.initials: T
authors.lastname: Iida
authors.forename: Keiji
authors.initials: K
authors.lastname: Hayata
authors.forename: Hiroki
authors.initials: H
authors.lastname: Yamaue
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001281:Atrial Fibrillation / Q000453:epidemiology* / Q000209:etiology / Q000517:prevention & control; D003106:Colon / Q000637:transplantation*; D004938:Esophageal Neoplasms / Q000150:complications / Q000601:surgery*; D016629:Esophagectomy / Q000379:methods*; D004944:Esophagoplasty / Q000379:methods*; D005260:Female; D006339:Heart Rate; D006801:Humans; D007082:Ileum / Q000637:transplantation*; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D009025:Morpholines / Q000627:therapeutic use; D011183:Postoperative Complications / Q000453:epidemiology* / Q000209:etiology / Q000517:prevention & control; D012307:Risk Factors; D013610:Tachycardia / Q000150:complications / Q000503:physiopathology; D014508:Urea / Q000031:analogs & derivatives / Q000627:therapeutic use
chemical_list: D000319:Adrenergic beta-Antagonists; D009025:Morpholines; C077049:landiolol; D014508:Urea